Last reviewed · How we verify
CoronaVac/CoronaVac
CoronaVac is an inactivated SARS-CoV-2 vaccine that stimulates the immune system to produce antibodies and cellular immunity against the virus.
CoronaVac is an inactivated SARS-CoV-2 vaccine that stimulates the immune system to produce antibodies and cellular immunity against the virus. Used for Prevention of COVID-19 in adults and adolescents.
At a glance
| Generic name | CoronaVac/CoronaVac |
|---|---|
| Sponsor | Institut Pasteur de Tunis |
| Drug class | Inactivated viral vaccine |
| Target | SARS-CoV-2 spike protein and other viral antigens |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
CoronaVac uses chemically inactivated whole SARS-CoV-2 virions to trigger both humoral (antibody) and cell-mediated immune responses. The inactivated virus particles are unable to replicate but retain antigenic epitopes that train the adaptive immune system to recognize and neutralize live virus upon exposure. This approach has been used successfully for decades in vaccines against other viral pathogens such as polio and influenza.
Approved indications
- Prevention of COVID-19 in adults and adolescents
Common side effects
- Injection site pain or swelling
- Fatigue
- Headache
- Myalgia
- Fever
Key clinical trials
- Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda (PHASE2)
- Immunogenicity and Safety Study of SARS-CoV-2 DNA Vaccine (ICCOV) (PHASE2)
- Heterologous Boost Immunization with Ad5-nCoV After Three-dose Priming with an Inactivated SARS-CoV-2 Vaccine (PHASE4)
- Community-based Sero-epidemiological Study of COVID-19
- Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study
- Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older (PHASE3)
- Immunogenicity Induced by COVID-19 Vaccines in Mexican Population
- Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |